SCAP and lung carcinoma: In addition to identifying candidate metabolites involved in SREBP-mediated lung cancer stemness and chemoresistance, we determined that the ensuing CSCs-like phenotype is induced by SREBP/SCAP-induced lipid metabolism reprogramming, and that this reprogramming therefore plays a key role in the development of chemoresistance by lung cancer cells.